☒
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☐
|
Soliciting Material under §240.14a-12
|
☒
|
No fee required.
|
|
☐
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
(5)
|
Total fee paid:
|
☐
|
Fee paid previously with preliminary materials.
|
|
☐
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
(1)
|
Amount Previously Paid:
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
|
(3)
|
Filing Party:
|
|
(4)
|
Date Filed:
|
1. |
“FOR” the election of Holly N. Alden, Christopher B. Morgan, Marla A. Ryan and Anne-Charlotte Windal to serve as directors on the Board until the 2019 annual meeting of Stockholders of the Company (including any and all adjournments, postponements, continuations or reschedulings thereof, or any other meeting of Stockholders held in lieu thereof, the “2019 Annual Meeting”) or until their respective successors are duly elected and qualified (the “Nomination Proposal”);
|
2. |
“FOR” the repeal of each provision of, or amendment to, the Bylaws of the Company, effective December 22, 2016 (the “Bylaws”) adopted by the Board without the approval of the Stockholders subsequent to December 22, 2016 and up to and including the conclusion of the 2018 Annual Meeting (the “Stockholder Proposal”);
|
3. |
“FOR” the ratification of the appointment of KPMG as the Company’s independent registered public accounting firm for fiscal year ending February 2, 2019;
|
4. |
“AGAINST” the approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the 2018 Annual Meeting.
|
|
Page
|
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
|
6
|
BACKGROUND TO THIS SOLICITATION
|
7
|
REASONS FOR THIS SOLICITATION
|
12
|
QUESTIONS AND ANSWERS RELATING TO THIS SOLICITATION
|
14
|
PROPOSAL NO. 1—ELECTION OF NOMINEES
|
21
|
PROPOSAL NO. 2—REPEAL OF CERTAIN PROVISIONS OF OR AMENDMENTS TO THE BYLAWS ADOPTED SUBSEQUENT TO DECEMBER 22, 2016
|
24
|
PROPOSAL NO. 3—RATIFICATION OF THE APPOINTMENT OF KPMG AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
25
|
PROPOSAL NO. 4—ADVISORY VOTE TO APPROVE THE COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS
|
25
|
OTHER PROPOSALS
|
26
|
NO APPRAISAL OR DISSENTER’S RIGHTS
|
26
|
SOLICITATION OF PROXIES
|
26
|
CERTAIN INFORMATION REGARDING THE PARTICIPANTS
|
27
|
CERTAIN RELATIONSHIPS
|
28
|
CERTAIN ADDITIONAL INFORMATION
|
30
|
INCORPORATION BY REFERENCE
|
31
|
ANNEX A—INFORMATION CONCERNING THE PARTICIPANTS IN THIS SOLICITATION
|
A-1
|
ANNEX B— SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND MANAGEMENT
|
B-1
|
·
|
Beginning on October 19, 2017, Nathan G. Miller, the principal of NGM Asset Management, LLC (“NGM”), met from time to time with members of the Board and Management, including Barry Erdos, Chairman of the Board, and Guggenheim Securities, LLC (“Guggenheim”), financial advisor to the Company, to discuss the Company’s financial performance and results of operations.
|
·
|
On December 27, 2017, Mr. Miller filed a Schedule 13D (the “Schedule 13D”) with the Securities and Exchange Commission (the “SEC”), disclosing a 7.8% interest in the Company. In the Schedule 13D, Mr. Miller disclosed, among other things, that he intended to engage in constructive discussions with the Board and Management as part of the Company’s publicly disclosed efforts to engage with stockholders. These discussions would include, but not be limited to, identifying qualified Board and Management candidates, increasing the size of the Board, optimizing the capital structure and improving corporate governance, compensation practices, investor relations and communication and operating performance. Mr. Miller also disclosed his intent to consider any and all potential corporate transactions.
|
·
|
On January 4, 2018, Mr. Miller sent a letter to the Board (the “January 4 Letter”) setting forth the potential terms of a merger transaction whereby the Company would become a private entity (the “Proposed Transaction”). Pursuant to the terms of the Proposed Transaction, Stockholders would be entitled to exchange their Common Stock for $2.75 in cash or, in certain circumstances, equity in the new entity formed by the Proposed Transaction. In the January 4 Letter, Mr. Miller requested that the Company grant limited waivers to allow him to speak to other stockholders to gauge their interest in such an equity rollover. The Company later denied such request.
|
·
|
On January 12, 2018, Mr. Miller and NGM entered into a confidentiality agreement with the Company (the “Confidentiality Agreement”) to facilitate discussions regarding a potential transaction with the Company. The Confidentiality Agreement included a limited standstill (which has subsequently expired) prohibiting Mr. Miller from soliciting proxies or making a public announcement or proposal regarding a potential transaction with the Company.
|
·
|
Between January 12, 2018 and March 9, 2018, Mr. Miller reviewed certain nonpublic materials provided by the Company (the “Company Materials”) and engaged in discussions with members of the Board and Management; Pepper Hamilton LLP (“Pepper Hamilton”), legal counsel to the Company; Guggenheim; and various potential financing sources. As a result of Mr. Miller’s review and discussions, Mr. Miller determined to no longer pursue the Proposed Transaction due to the Company’s poor financial performance and liquidity issues. Accordingly, Mr. Miller developed cost-cutting and revenue enhancement recommendations to address such issues and discussed them with the Board and Management. Thereafter, Mr. Miller engaged in discussions with Mr. Erdos regarding capital-raising methods for the Company.
|
·
|
On March 14, 2018, Mr. Miller sent a letter to the Board proposing that the Company sell convertible preferred stock to private third-party investors in order to raise capital (the “PIPE Proposal”). The terms of the PIPE Proposal reflected an investment of $10 million in cash and the surrender of 1.56 million shares of Common Stock owned by such investors in exchange for securities consisting of dividend-bearing preferred stock convertible into Common Stock at $1.50 per share and warrants to purchase 5.5392 million shares of Common Stock at not more than $2.46 per share, which reflected fully diluted ownership of 49.9% to the investors. Such terms of the PIPE Proposal reflected an approximate 20% discount to the Common Stock price at the time oral negotiations began. The Investors offered this price because there would be a lack of liquidity or active trading market for the proposed preferred stock and the Investors believed there was significant risk in effecting a turnaround as a minority stockholder. In addition, the proposed price and valuation terms were based on the Investors’ evaluation of certain nonpublic information provided by the Company under the Confidentiality Agreement. In connection with the PIPE Proposal, Mr. Miller proposed that four new directors, including two third-party investors and two mutually-agreed upon individuals, be elected to the Board. Mr. Miller also proposed that the Company appoint a new CEO and suggested Marla A. Ryan for the position. Mr. Miller also recommended that the Company engage a cost consultant.
|
·
|
Between March 14, 2018 and March 21, 2018, Mr. Miller attempted to engage in additional discussions with the Company regarding the PIPE Proposal, but did not receive a definitive response or counterproposal. As a result of the failure of the Company to engage in further negotiations, Mr. Miller determined to no longer pursue the PIPE Proposal.
|
·
|
On March 21, 2018, Mr. Miller sent a letter to the Secretary of the Company requesting the Company’s questionnaire and the written representation and agreement, each as required by Article I, Section 7(a)(iii) of the Bylaws (together, the “Director Nomination Materials”).
|
·
|
On March 22, 2018, the Company sent Mr. Miller the Director Nomination Materials.
|
·
|
Also on March 22, 2018, representatives of Cadwalader, Wickersham & Taft LLP (“Cadwalader”), legal counsel to Mr. Miller, called a representative of Pepper Hamilton, with a proposal to add two new directors to the Board, pursuant to which two incumbent directors would either resign or not stand for election at the 2018 Annual Meeting.
|
·
|
On March 23, 2018, a representative of Pepper Hamilton communicated to a representative of Cadwalader that the Company was willing to consider an expansion of the Board in order to add one or two independent directors chosen by Mr. Miller; however, the Company’s proposal to permit the Investors to appoint a second director was conditioned upon the Investors’ ability to control at least 15% of the outstanding Common Stock. As publicly disclosed in the Schedule 13D, the Investors do not possess control over this amount of shares, and as such, the Company’s proposal to add two new independent directors was not viewed by the Investors as an offer capable of acceptance.
|
·
|
On March 24, 2018, Mr. Miller submitted to the Secretary of the Company a formal notice of intent (the “Notice”) to present a stockholder proposal and nominate candidates for election to the Board, in each case, at the 2018 Annual Meeting. Mr. Miller submitted a stockholder proposal for consideration at the 2018 Annual Meeting proposing the repeal of each provision of, or amendment to, the Bylaws adopted by the Board without the approval of the Stockholders subsequent to December 22, 2016, which is the date of the last publicly available Bylaws. The Notice stated that, at the 2018 Annual Meeting, Mr. Miller intended to nominate for election as directors of the Company, (i) Christopher B. Morgan, (ii) Marla A. Ryan and (iii) Anne-Charlotte Windal. For more information about the Nominees and the Stockholder Proposal, see the sections of this Proxy Statement entitled “Proposal No. 1—Election Of Nominees” and “Proposal No. 2—Repealing Of Certain Provisions Of Or Amendments To The Bylaws Adopted Since December 22, 2016.”
|
·
|
On March 25, 2018, Ms. Ryan received a call from a representative of Guggenheim. Ms. Ryan has advised the Investors that on such call, the Guggenheim representative spoke positively of her candidacy.
|
·
|
On March 26, 2018, the Investors filed Amendment No. 1 to the Schedule 13D with the SEC disclosing a collective 8.8% interest in the Company. In the Schedule 13D, the Investors disclosed Mr. Miller’s submission of the Notice to the Company and the Investors’ intent to conduct a proxy solicitation to elect the Nominees to the Board and approve the Stockholder Proposal at the 2018 Annual Meeting.
|
·
|
On March 27, 2018, the Investors filed Amendment No. 2 to the Schedule 13D with the SEC disclosing that if the Nominees are elected to the Board at the 2018 Annual Meeting, each of the Investors and the Nominees would support expanding the Board and adding representation for Orchestra-Prémaman S.A. (“Orchestra”) to the Board, if Orchestra desires such representation, so that the Board will include additional stockholder representation.
|
·
|
On March 28, 2018, the Company sent a letter to Mr. Miller acknowledging receipt of the Notice and stating that the Company had no objections to the Notice other than asserting that certain sections of each Nominee’s questionnaire required handwritten initials instead of typed initials, although no such requirement was included in the questionnaire or the Bylaws.
|
·
|
On March 30, 2018, Mr. Miller delivered to the Company a letter attaching updated questionnaires in response to the Company’s request.
|
·
|
Also on March 30, 2018, Mr. Miller sent a letter to the Company informing the Company that he would be willing to agree to the use of a proxy card that allowed stockholders to vote for each of the Investors’ and the Company’s nominees if the Company was willing to do the same. In the letter, Mr. Miller stated his belief that the Board should act in good faith to provide stockholders with a meaningful choice at the 2018 Annual Meeting by committing to use a universal proxy card that would include all of the nominees proposed, regardless of who has proposed such nominees, because it was a hallmark of good corporate governance. The Investors filed the letter with the SEC as an exhibit to Amendment No. 3 to the Schedule 13D.
|
·
|
On April 3, 2018, the Company filed a Form 8-K stating that two directors selected by Orchestra, Pierre-André Mestre and Jean-Claude Jacomin (the “Orchestra Directors”) were appointed to the Board pursuant to an agreement with Orchestra (the “Support Agreement”) which also provided for a vote lock-up. As a result, the size of the Board was increased from four directors to six directors.
|
·
|
On April 4, 2018, Kristen D. Han, the Company’s Vice President and General Counsel, sent a letter to Mr. Miller notifying him that the Board had unanimously rejected the use of a universal proxy card. The letter stated that a universal proxy card “would not be in the best interests of the Company’s stockholders” because, among other reasons, it would create “significant risk of confusion that could result in disenfranchisement of certain stockholders.”
|
·
|
On April 5, 2018, a representative of Pepper Hamilton communicated to representatives of Cadwalader that the Company was willing to consider an immediate expansion of the Board to add one of Mr. Miller’s nominees to the Board, and would consider adding another of Mr. Miller’s nominees to the Board if and when a vacancy occurs on the Board.
|
·
|
On April 6, 2018, Mr. Erdos sent an email to Mr. Miller requesting a response to the Company’s settlement offer.
|
·
|
On April 9, 2018, a representative of Cadwalader sent an email to the Company and a representative of Pepper Hamilton stating that the settlement offer made on April 5, 2018 was not acceptable and on behalf of Mr. Miller sent a letter requesting certain stockholder list materials (the “Demand Letter”) pursuant to Section 220 of the Delaware General Corporation Law (“DGCL”).
|
·
|
On April 10, 2018, Mr. Miller sent a letter to the Board (the “April 10 Letter”) highlighting the Company’s manifest financial and operational failures and the Board’s entrenchment tactics. In the letter, Mr. Miller expressed his concern at the lack of disclosure regarding the Company’s announced “turnaround plan,” the termination of Mr. Weinstein and the CEO search process. In particular, Mr. Miller noted that, in the three years since the Company first announced its turnaround plan, the Company’s stock price fell by 83%, the Company’s revenue declined by $116 million and the Company’s net income of $10.7 million deteriorated into a net loss of $8.4 million.
|
·
|
Also on April 10, 2018, a representative of Pepper Hamilton called a representative of Cadwalader to propose a settlement offer, which offer consisted of the addition of two of Mr. Miller’s nominees to the Board, with two incumbent directors not standing for re-election at the 2018 Annual Meeting.
|
·
|
On April 11, 2018, representatives of Cadwalader called a representative of Pepper Hamilton to propose a settlement offer, which offer called for a six-member Board comprised of four of the Investors’ nominees, Mr. Mestre and one other incumbent director. The representatives of Cadwalader also proposed an alternate settlement offer on such call, which offer called for the resignation of both Orchestra Directors and a six-member Board, comprised of four of the Investors’ nominees and two incumbent directors.
|
·
|
On April 12, 2018, in light of the changes announced in the Company’s Form 8-K filed on April 3, 2018, Mr. Miller submitted to the Secretary of the Company a formal notice of intent (the “Supplemental Notice”) to nominate two additional candidates for election to the Board at the 2018 Annual Meeting, Holly N. Alden and Nathan G. Miller. The Supplemental Notice stated that, at the 2018 Annual Meeting, the Investors intended to nominate for election as directors of the Company, (i) Holly N. Alden, (ii) Nathan G. Miller, (iii) Christopher B. Morgan, (iv) Marla A. Ryan and (v) Anne-Charlotte Windal. For more information about the Nominees, see the section of this Proxy Statement entitled “Proposal No. 1—Election Of Nominees.”
|
·
|
Also on April 12, 2018, the Company filed a Form 8-K stating that on April 11, 2018, Mr. Jacomin, who had been appointed to the Board only nine days earlier, had resigned, effective immediately. The Company also disclosed that on April 12, 2018, the Board decreased the size of the Board from six directors to five directors. The Company noted that pursuant to the Support Agreement and subject to the conditions set forth therein, Orchestra has the right to name a substitute individual to replace Mr. Jacomin on the Board. The Company did not announce who Orchestra intends to name or when Orchestra will exercise such right.
|
·
|
Later on April 12, 2018, a representative of Pepper Hamilton called representatives of Cadwalader to communicate that the Company was willing to consider adding three of Mr. Miller’s nominees to the Board. Representatives of Cadwalader later called a representative of Pepper Hamilton to propose a counter offer, which offer called for a seven-member Board comprised of four of the Investors’ nominees, two incumbent directors and an additional individual the Board had previously vetted and invited to serve on the Board.
|
·
|
Also on April 12, 2018, Ronald J. Masciantonio, the Company’s Executive Vice President and Chief Administrative Officer, sent a letter to Mr. Miller (the “April 12 Letter”) asserting that Mr. Miller’s April 10 Letter should have included certain disclosures regarding the Confidentiality Agreement, the Proposed Transaction, the PIPE Proposal and the position of the Nominees on the Proposed Transaction and the PIPE Proposal, all of which Mr. Miller was prohibited from disclosing to third parties under the Confidentiality Agreement. In the April 12 Letter, the Company provided written consent under the Confidentiality Agreement for Mr. Miller to include such disclosures in his SEC filings, which consent expressly excluded the Company Materials.
|
·
|
On April 13, 2018, a representative of Pepper Hamilton communicated to a representative of Cadwalader that the counter offer made on April 12, 2018 was not acceptable.
|
·
|
Also on April 13, 2018, the Company filed a Form 8-K with the SEC announcing that the composition of the Board would change for the third time in a two-week period because Michael J. Blitzer would not be standing for reelection to the Board at the 2018 Annual Meeting. The Company also stated that, instead of immediately reducing the size of the Board accordingly, as was done following Mr. Jacomin’s resignation, the Board had resolved that the size of the Board would decrease from five directors to four directors effective upon the commencement of the 2018 Annual Meeting.
|
·
|
Additionally, on April 13, 2018, the Company filed a preliminary proxy statement with the SEC announcing a slate of four nominees for election at the 2018 Annual Meeting and stating that the Board did not endorse any of the Nominees. The Company also stated that Orchestra intends to exercise its right to name a substitute person to replace Mr. Jacomin on the Board, but did not indicate whether Orchestra intended to exercise this right before or after the 2018 Annual Meeting.
|
·
|
Later on April 13, 2018, Mr. Erdos sent a letter to Ms. Ryan and Ms. Windal requesting Ms. Ryan and Ms. Windal’s consent for the Company to include each of them on the Company’s slate of nominees for election at the 2018 Annual Meeting and solicit votes in favor of their election. Ms. Ryan and Ms. Windal did not provide such consent. The full text of the letter follows:
|
·
|
On April 16, 2018, Mr. Miller sent a letter to the Board. In the letter, Mr. Miller noted that the recent Board size and composition changes, enacted long after the director nomination deadline for the 2018 Annual Meeting, caused significant uncertainty in even the most basic details regarding the election of directors at the 2018 Annual Meeting and appeared to be “an attempt to gain an improper advantage” in such election. In the letter, Mr. Miller requested that the Board refrain from engaging in any further manipulation of the Board’s composition for the benefit of all Stockholders, and that the Board make an unequivocal statement as to the maximum number of Board seats up for election at the 2018 Annual Meeting, the maximum number of individuals Mr. Miller may nominate and whether the Board would allow Orchestra to circumvent stockholder democracy by nominating Mr. Jacomin’s replacement after the 2018 Annual Meeting.
|
·
|
Also on April 16, 2018, a representative of the Company sent a letter to Mr. Miller responding to the Demand Letter (the “Response Letter”). In the Response Letter, the Company stated it would provide Mr. Miller with certain information requested in the Demand Letter.
|
·
|
On April 17, 2018, Mr. Erdos sent a letter to Mr. Miller stating that, as of the date thereof, there were five members on the Board, four of whom were nominated by the Board for election at the 2018 Annual Meeting, and four seats up for election at the 2018 Annual Meeting. The letter also stated that Orchestra’s right to nominate Mr. Jacomin’s replacement is not required to be exercised by a specific date, and reiterated Mr. Erdos’ offer to include Ms. Ryan and Ms. Windal on the Company’s slate. The letter did not address how many seats would be up for election if Orchestra exercises its right to a replacement before the 2018 Annual Meeting.
|
·
|
On April 20, 2018, in light of the changes announced in the Company’s Form 8-K filed on April 13, 2018, Mr. Miller submitted to the Secretary of the Company an update and supplement to the Notice and the Supplemental Notice (the “Update and Supplement”). The Update and Supplement notified the Company that Mr. Miller had elected to reduce the size of the slate from five nominees to four nominees and withdraw his nomination of himself as a Nominee. In the Update and Supplement, Mr. Miller reserved the right to further nominate, substitute or add additional persons, including himself, in the event that the Company once again increased the number of directorships.
Nathan G. Miller was born on November 2, 1978. Mr. Miller has served as the Managing Partner, Chief Investment Officer and Portfolio Manager of NGM, a family office he founded, since 2012. In addition, Mr. Miller served as a senior analyst at Impala Asset Management, LLC in 2015. Prior to founding NGM, Mr. Miller served as a portfolio manager at Surveyor Capital at Citadel LLC from 2011 to 2012. In this role, Mr. Miller led an analyst team focusing on the industrials sector. From 2009 to 2011, Mr. Miller was a Portfolio Manager and the Co-Head of the Equity Long/Short Desk at Royal Bank of Canada Capital Markets, during which time he oversaw risk management and the structure of investment teams across all sectors. Prior to that, Mr. Miller held various analyst roles at SAC Capital Advisors LP and Goldman, Sachs & Co., focusing on various sectors, including the industrials and retail industries. Mr. Miller received a B.A. in Economics and a B.S. in Biomedical Engineering, Electrical & Computer Engineering from the Johns Hopkins University. Mr. Miller’s principal business address is 27 Pine Street, Suite 700, New Canaan, Connecticut 06840.
We believe that the attributes, skills and qualifications that Mr. Miller has obtained through his extensive experience in analyzing the financial performance of companies as well as his alignment with stockholders through his significant monetary interest in the Company’s success will provide the Board and the Company with valuable financial knowledge and insight into value-maximizing strategies.
|
·
|
On April 20, 2018, the Investors filed a preliminary proxy statement with the SEC.
|
·
|
On April 23, 2018, the Company filed a revised preliminary proxy statement and a definitive proxy statement with the SEC.
|
·
|
On April 24, 2018, Mr. Miller sent a letter to the Board (the “April 24 Letter”) renewing his request, made two weeks prior, for certain stockholder lists, including a Non-Objecting Beneficial Ownership or "NOBO" list, as described in the Demand Letter. In the letter, Mr. Miller stated that the Investors viewed the Company’s continued failure to deliver such stockholder lists as yet another attempt by the Company to avoid accountability to stockholders, gain an improper tactical advantage in the election and further entrench the incumbent directors. The Investors filed the letter with the SEC as an exhibit to Amendment No. 7 to the Schedule 13D.
|
·
|
On April 25, 2018, the Company sent a letter to Mr. Miller, stating that it would provide the stockholder lists requested in the April 24 Letter to Mr. Miller.
|
·
|
On April 26, 2018, Mr. Miller sent a letter to the Board asserting that the Investors had been informed by certain Stockholders who were not on any stockholder list provided to the Investors that they were receiving calls from the Company soliciting their vote. Mr. Miller expressed the view that such names must be on either a NOBO or other list that that Company’s proxy solicitor is using, and again requested the NOBO list.
|
·
|
On April 27, 2018, the Investors filed a revised preliminary proxy statement with the SEC.
|
·
|
the Company’s stock price declined 84%;4
|
·
|
the Company’s book value per share declined by 67%;5
|
·
|
the Company entered into and then terminated a merger with Orchestra;
|
·
|
the Company changed CEOs three times;
|
·
|
the Company’s revenue declined by $111 million; and
|
·
|
the Company’s recorded net income of $10.7 million in fiscal year 2014 deteriorated into a net loss of $10.2 million in fiscal year 2017.6
|
1. |
“FOR” the election of Holly N. Alden, Christopher B. Morgan, Marla A. Ryan and Anne-Charlotte Windal to serve as directors on the Board until the 2019 Annual Meeting or until their respective successors are duly elected and qualified;
|
2. |
“FOR” the repeal of each provision of, or amendment to, the Bylaws adopted by the Board without the approval of the Stockholders subsequent to December 22, 2016 and up to and including the conclusion of the 2018 Annual Meeting;
|
3. |
“FOR” the ratification of the appointment of KPMG as the Company’s independent registered public accounting firm for fiscal year ending February 2, 2019; and
|
4. |
“AGAINST” the approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the 2018 Annual Meeting.
|
Name and Age
|
Business Address
|
Principal Occupation or Employment and Public Company
Directorships, in each case During the Last Five Years
|
||
Holly N. Alden (50)
|
69 White Pine Canyon Road,
Park City, UT 84060
|
Holly N. Alden is the co-founder of Stance Inc., a sock manufacturing company founded in 2009. Prior to founding Stance, Ms. Alden helped to found Skullcandy Inc., an audio accessory company, where she was employed from 2003 to 2010. Prior to that, Ms. Alden served as a partner at National Snowboard Inc., an events and marketing company. In 2016, Ms. Alden also co-founded two 501(c)(3) organizations, the Alden Charitable Trust and Encircle. Ms. Alden currently serves as the President of the Alden Charitable Trust and the Treasurer of Encircle. Additionally, Ms. Alden serves as a director of Sunstone Education Foundation Incorporated. Ms. Alden received a B.A. in Behavioral Sciences from the Metropolitan State University of Denver.
Ms. Alden has over 25 years of marketing, branding and financial experience. We believe that the attributes, skills and qualifications that Ms. Alden has obtained through her entrepreneurial experience will provide the Board and the Company with a crucial perspective on evaluating and pursuing future business opportunities.
|
||
Christopher B. Morgan (46)
|
152 West 57th Street, 50th Floor, New York, NY 10019
|
Christopher B. Morgan has been a senior analyst at Kingdon Capital Management, L.L.C. since 2014, researching consumer discretionary, retail and business services. Prior to joining Kingdon, Mr. Morgan was a senior analyst at Centerline Investments Partners from March 2013 to October 2014, a consultant at Suvretta Capital Partners LP from 2011 to 2012 and a Managing Director at Karsh Capital Management from 2006 to 2010, where Mr. Morgan was responsible for stock selection in the consumer discretionary and financial services sectors in a $3.5 billion global equity hedge fund. From 2004 to 2006, Mr. Morgan was a Partner at Copper Beech Capital Management responsible for equity investments in mid-cap consumer discretionary, leisure, business services and specialty financial services. Mr. Morgan served as an equity analyst at Hunter Global Investors from 2001 to 2004 and as an equity research analyst at Donaldson, Lufkin & Jenrette from 1995 to 2000, covering banks and financial services. Prior to that, Mr. Morgan was a credit analyst at Chemical Bank in the corporate banking/commercial lending division. Mr. Morgan received a B.A. in Psychology from Dartmouth College.
We believe that the attributes, skills and qualifications that Mr. Morgan has obtained through his experience in analyzing the financial performance of companies will provide the Board and the Company with valuable insight regarding analyzing and improving the financial performance of the Company.
|
Name and Age
|
Business Address | Principal Occupation or Employment and Public Company
Directorships, in each case During the Last Five Years
|
||
Marla A. Ryan (51)
|
80 Chambers Street, Apt 13C, New York, NY 10007
|
Marla A. Ryan is the founder and Chief Executive Officer of Lola Advisors LLC, a business consultancy working in the apparel, beauty and wellness sector. Prior to founding Lola Advisors LLC, Ms. Ryan was employed by Lands’ End from 2009 through 2017, most recently serving as Senior Vice President of Retail. In this role, Ms. Ryan managed the Retail business unit, including Lands’ End shops at Sears, retail and outlet stores, and served as a member of the Executive Leadership Team. From 2009 to 2012, Ms. Ryan held various senior positions at Lands’ End, including Senior Vice President of Global Omni-Merchandising and Vice President of Retail. From 2002 to 2009, Ms. Ryan served in various senior positions at J.Crew, including Vice President of Crewcuts, J.Crew’s children’s apparel division. Prior to that, she served in various merchandising and management roles at Brooks Brothers, American Eagle, Abercrombie & Fitch and The Gap, Inc.
Ms. Ryan has over 25 years of comprehensive functional and executive experience across e-commerce and retail, branch launch and strategy, merchandising, digital marketing, inventory management, real estate and store operations. We believe that Ms. Ryan’s extensive experience in the specialty retail industry will provide valuable skills and insights to the Board.
|
Anne-Charlotte Windal (48)
|
201 East 83rd Street, Apt 18A, New York, NY 10028
|
Anne-Charlotte Windal is the founder of ACW Consulting, LLC, through which she provides strategic advisory services to consumer goods and retail companies, including Starbucks, Bath & Body Works and American Eagle. From 2013 to 2016, Ms. Windal was a Senior Analyst for Bernstein Research. In this role, she led a team that provided in-depth investment research and financial analysis on the U.S. specialty retail sector. Prior to joining Bernstein Research, Ms. Windal served as a Partner for NERVE Group, a strategy and creative consultancy to consumer and retail companies, including Johnson & Johnson, Bath & Body Works, Starbucks, PepsiCo and Avon. From 2008 to 2010, she served as Senior Vice President and General Manager of the strategy and design division at New York & Company, where she served as a member of the Executive Committee. Prior to that, Ms. Windal held various senior positions at L Brands, driving strategic growth projects for Victoria’s Secret, Bath & Body Works, Henri Bendel and Express. Ms. Windal received an M.S. in Management with a concentration in Finance from Ecole des Hautes Etudes Commerciales and an M.B.A. with a concentration in Marketing and Finance from Columbia Business School.
We believe that Ms. Windal’s broad expertise in growth strategy, strategic and merchandising planning, consumer insight, retail and product innovation will make her a valuable addition to the Board.
|
• |
signing, dating and returning the enclosed GOLD proxy card or any other later-dated proxy in the postage-paid envelope provided;
|
• |
delivering to the Secretary or any other officer of the Company a written notice of revocation c/o Destination Maternity Corporation, 232 Strawbridge Drive, Moorestown, New Jersey 08057; or
|
• |
attending the 2018 Annual Meeting and voting in person.
|
Name
|
Beneficial Ownership
|
|
Nathan G. Miller
|
1,136,727 shares of Common Stock
|
|
Peter O’Malley
|
143,106 shares of Common Stock
|
|
Holly N. Alden
|
0 shares of Common Stock
|
|
Christopher B. Morgan
|
0 shares of Common Stock
|
|
Marla A. Ryan
|
0 shares of Common Stock
|
|
Anne-Charlotte Windal
|
0 shares of Common Stock
|
Thank you for your support. | |
|
NATHAN G. MILLER
|
|
PETER O’MALLEY
|
|
HOLLY N. ALDEN
|
|
CHRISTOPHER B. MORGAN
|
|
MARLA A. RYAN
|
|
ANNE-CHARLOTTE WINDAL
|
Trade Date
|
Buy/Sell
|
Trade Quantity
|
Net Price
|
Security Description
|
||||
12/15/2017
|
Buy
|
700
|
$2.59
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,900
|
$2.59
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,200
|
$2.59
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,900
|
$2.57
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,900
|
$2.58
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,900
|
$2.55
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,900
|
$2.57
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,900
|
$2.56
|
Common Stock
|
||||
12/15/2017
|
Buy
|
9,900
|
$2.56
|
Common Stock
|
||||
12/8/2017
|
Buy
|
200
|
$2.51
|
Common Stock
|
||||
12/8/2017
|
Buy
|
4,800
|
$2.51
|
Common Stock
|
||||
12/7/2017
|
Buy
|
90
|
$2.38
|
Common Stock
|
||||
12/7/2017
|
Buy
|
227
|
$2.32
|
Common Stock
|
||||
12/7/2017
|
Buy
|
4,140
|
$2.36
|
Common Stock
|
||||
12/7/2017
|
Buy
|
3,278
|
$2.36
|
Common Stock
|
||||
12/7/2017
|
Buy
|
1,343
|
$2.37
|
Common Stock
|
||||
12/7/2017
|
Buy
|
1,100
|
$2.37
|
Common Stock
|
||||
12/7/2017
|
Buy
|
50
|
$2.36
|
Common Stock
|
||||
12/7/2017
|
Buy
|
1,621
|
$2.37
|
Common Stock
|
||||
12/7/2017
|
Buy
|
2,391
|
$2.37
|
Common Stock
|
||||
12/7/2017
|
Buy
|
300
|
$2.37
|
Common Stock
|
||||
11/17/2017
|
Buy
|
100
|
$2.70
|
Common Stock
|
||||
11/6/2017
|
Buy
|
9,900
|
$2.53
|
Common Stock
|
||||
11/6/2017
|
Buy
|
604
|
$2.49
|
Common Stock
|
||||
11/6/2017
|
Buy
|
9,296
|
$2.49
|
Common Stock
|
||||
11/3/2017
|
Buy
|
5,000
|
$2.42
|
Common Stock
|
||||
11/3/2017
|
Buy
|
5,000
|
$2.38
|
Common Stock
|
||||
11/2/2017
|
Buy
|
401
|
$2.33
|
Common Stock
|
||||
11/2/2017
|
Buy
|
1,300
|
$2.34
|
Common Stock
|
||||
11/2/2017
|
Buy
|
600
|
$2.34
|
Common Stock
|
||||
11/1/2017
|
Buy
|
9,900
|
$2.30
|
Common Stock
|
||||
11/1/2017
|
Buy
|
700
|
$2.28
|
Common Stock
|
||||
11/1/2017
|
Buy
|
5,000
|
$2.28
|
Common Stock
|
Trade Date | Buy/Sell | Trade Quantity | Net Price | Security Description | ||||
11/1/2017
|
Buy
|
100
|
$2.29
|
Common Stock
|
||||
11/1/2017
|
Buy
|
2,100
|
$2.29
|
Common Stock
|
||||
11/1/2017
|
Buy
|
1,900
|
$2.32
|
Common Stock
|
||||
11/1/2017
|
Buy
|
6,780
|
$2.34
|
Common Stock
|
||||
11/1/2017
|
Buy
|
3,120
|
$2.37
|
Common Stock
|
||||
11/1/2017
|
Buy
|
400
|
$2.37
|
Common Stock
|
||||
11/1/2017
|
Buy
|
8,000
|
$2.37
|
Common Stock
|
||||
11/1/2017
|
Buy
|
4,100
|
$2.38
|
Common Stock
|
||||
11/1/2017
|
Buy
|
585
|
$2.38
|
Common Stock
|
||||
11/1/2017
|
Buy
|
300
|
$2.38
|
Common Stock
|
||||
11/1/2017
|
Buy
|
2,015
|
$2.38
|
Common Stock
|
||||
11/1/2017
|
Buy
|
2,267
|
$2.39
|
Common Stock
|
||||
11/1/2017
|
Buy
|
700
|
$2.42
|
Common Stock
|
||||
11/1/2017
|
Buy
|
665
|
$2.41
|
Common Stock
|
||||
11/1/2017
|
Buy
|
3,735
|
$2.44
|
Common Stock
|
||||
10/31/2017
|
Buy
|
1,200
|
$2.24
|
Common Stock
|
||||
10/31/2017
|
Buy
|
3,000
|
$2.26
|
Common Stock
|
||||
10/31/2017
|
Buy
|
2,300
|
$2.27
|
Common Stock
|
||||
10/31/2017
|
Buy
|
1,200
|
$2.28
|
Common Stock
|
||||
10/31/2017
|
Buy
|
5,500
|
$2.28
|
Common Stock
|
||||
10/31/2017
|
Buy
|
2,705
|
$2.30
|
Common Stock
|
||||
10/31/2017
|
Buy
|
6,300
|
$2.31
|
Common Stock
|
||||
10/30/2017
|
Buy
|
4,101
|
$2.48
|
Common Stock
|
||||
10/30/2017
|
Buy
|
3,802
|
$2.48
|
Common Stock
|
||||
10/30/2017
|
Buy
|
21,997
|
$2.48
|
Common Stock
|
||||
10/30/2017
|
Buy
|
100
|
$2.48
|
Common Stock
|
||||
10/30/2017
|
Buy
|
100
|
$2.43
|
Common Stock
|
||||
10/30/2017
|
Buy
|
500
|
$2.43
|
Common Stock
|
||||
10/30/2017
|
Buy
|
200
|
$2.43
|
Common Stock
|
||||
10/30/2017
|
Buy
|
7,500
|
$2.46
|
Common Stock
|
||||
10/30/2017
|
Buy
|
4,500
|
$2.48
|
Common Stock
|
||||
10/30/2017
|
Buy
|
601
|
$2.44
|
Common Stock
|
||||
10/30/2017
|
Buy
|
100
|
$2.43
|
Common Stock
|
||||
10/30/2017
|
Buy
|
300
|
$2.43
|
Common Stock
|
||||
10/30/2017
|
Buy
|
4,750
|
$2.43
|
Common Stock
|
||||
10/26/2017
|
Buy
|
1,500
|
$2.91
|
Common Stock
|
||||
10/26/2017
|
Buy
|
6,400
|
$2.90
|
Common Stock
|
||||
10/26/2017
|
Buy
|
2,000
|
$2.91
|
Common Stock
|
||||
10/26/2017
|
Buy
|
9,900
|
$2.79
|
Common Stock
|
||||
10/26/2017
|
Buy
|
300
|
$2.84
|
Common Stock
|
||||
10/26/2017
|
Buy
|
100
|
$2.83
|
Common Stock
|
||||
10/26/2017
|
Buy
|
200
|
$2.83
|
Common Stock
|
||||
10/26/2017
|
Buy
|
1,600
|
$2.83
|
Common Stock
|
||||
10/26/2017
|
Buy
|
7,700
|
$2.85
|
Common Stock
|
||||
10/25/2017
|
Buy
|
100
|
$2.87
|
Common Stock
|
||||
10/25/2017
|
Buy
|
300
|
$2.89
|
Common Stock
|
||||
10/25/2017
|
Buy
|
500
|
$2.87
|
Common Stock
|
||||
10/25/2017
|
Buy
|
1,230
|
$2.87
|
Common Stock
|
||||
10/25/2017
|
Buy
|
9,900
|
$2.89
|
Common Stock
|
||||
10/25/2017
|
Buy
|
100
|
$2.88
|
Common Stock
|
||||
10/25/2017
|
Buy
|
100
|
$2.88
|
Common Stock
|
||||
10/25/2017
|
Buy
|
2,070
|
$2.89
|
Common Stock
|
||||
10/25/2017
|
Buy
|
5,500
|
$2.89
|
Common Stock
|
||||
10/25/2017
|
Buy
|
2,700
|
$2.90
|
Common Stock
|
||||
10/25/2017
|
Buy
|
9,900
|
$2.92
|
Common Stock
|
||||
10/25/2017
|
Buy
|
3,139
|
$2.90
|
Common Stock
|
||||
10/25/2017
|
Buy
|
13,228
|
$2.90
|
Common Stock
|
Trade Date | Buy/Sell | Trade Quantity | Net Price | Security Description | ||||
10/24/2017
|
Buy
|
400
|
$2.81
|
Common Stock
|
||||
10/24/2017
|
Buy
|
150
|
$2.82
|
Common Stock
|
||||
10/24/2017
|
Buy
|
1,300
|
$2.83
|
Common Stock
|
||||
10/24/2017
|
Buy
|
100
|
$2.83
|
Common Stock
|
||||
10/24/2017
|
Buy
|
400
|
$2.85
|
Common Stock
|
||||
10/24/2017
|
Buy
|
200
|
$2.82
|
Common Stock
|
||||
10/24/2017
|
Buy
|
600
|
$2.83
|
Common Stock
|
||||
10/24/2017
|
Buy
|
400
|
$2.84
|
Common Stock
|
||||
10/24/2017
|
Buy
|
600
|
$2.84
|
Common Stock
|
||||
10/24/2017
|
Buy
|
260
|
$2.84
|
Common Stock
|
||||
10/24/2017
|
Buy
|
2,700
|
$2.91
|
Common Stock
|
||||
10/24/2017
|
Buy
|
200
|
$2.92
|
Common Stock
|
||||
10/24/2017
|
Buy
|
3,100
|
$2.91
|
Common Stock
|
||||
10/24/2017
|
Buy
|
3,900
|
$2.91
|
Common Stock
|
||||
10/24/2017
|
Buy
|
100
|
$2.95
|
Common Stock
|
||||
10/24/2017
|
Buy
|
8
|
$2.90
|
Common Stock
|
||||
10/24/2017
|
Buy
|
100
|
$2.90
|
Common Stock
|
||||
10/24/2017
|
Buy
|
400
|
$2.93
|
Common Stock
|
||||
10/24/2017
|
Buy
|
7,933
|
$2.92
|
Common Stock
|
||||
10/24/2017
|
Buy
|
100
|
$2.90
|
Common Stock
|
||||
10/24/2017
|
Buy
|
850
|
$2.96
|
Common Stock
|
||||
10/24/2017
|
Buy
|
1,000
|
$3.01
|
Common Stock
|
||||
10/24/2017
|
Buy
|
8,050
|
$3.01
|
Common Stock
|
||||
10/24/2017
|
Buy
|
1,450
|
$2.83
|
Common Stock
|
||||
10/24/2017
|
Buy
|
3,789
|
$2.83
|
Common Stock
|
||||
10/24/2017
|
Buy
|
700
|
$2.83
|
Common Stock
|
||||
10/24/2017
|
Buy
|
1,700
|
$2.83
|
Common Stock
|
||||
10/23/2017
|
Buy
|
50,000
|
$2.65
|
Common Stock
|
||||
10/23/2017
|
Buy
|
100
|
$2.82
|
Common Stock
|
||||
10/23/2017
|
Buy
|
1
|
$2.83
|
Common Stock
|
||||
10/23/2017
|
Buy
|
5,402
|
$2.83
|
Common Stock
|
||||
10/23/2017
|
Buy
|
1,000
|
$2.83
|
Common Stock
|
||||
10/23/2017
|
Buy
|
900
|
$2.86
|
Common Stock
|
||||
10/23/2017
|
Buy
|
500
|
$2.87
|
Common Stock
|
||||
10/23/2017
|
Buy
|
600
|
$2.86
|
Common Stock
|
||||
10/23/2017
|
Buy
|
100
|
$2.93
|
Common Stock
|
||||
10/23/2017
|
Buy
|
237
|
$2.89
|
Common Stock
|
||||
10/23/2017
|
Buy
|
387
|
$2.90
|
Common Stock
|
||||
10/23/2017
|
Buy
|
300
|
$2.89
|
Common Stock
|
||||
10/23/2017
|
Buy
|
200
|
$2.89
|
Common Stock
|
||||
10/23/2017
|
Buy
|
7,361
|
$2.90
|
Common Stock
|
||||
10/23/2017
|
Buy
|
2,900
|
$2.90
|
Common Stock
|
||||
10/23/2017
|
Buy
|
1,570
|
$2.90
|
Common Stock
|
||||
10/23/2017
|
Buy
|
943
|
$2.92
|
Common Stock
|
||||
10/23/2017
|
Buy
|
400
|
$2.91
|
Common Stock
|
||||
10/23/2017
|
Buy
|
900
|
$2.91
|
Common Stock
|
||||
10/23/2017
|
Buy
|
6,429
|
$2.91
|
Common Stock
|
||||
10/12/2017
|
Buy
|
1,700
|
$1.78
|
Common Stock
|
||||
10/12/2017
|
Buy
|
900
|
$1.80
|
Common Stock
|
||||
10/12/2017
|
Buy
|
900
|
$1.80
|
Common Stock
|
||||
10/12/2017
|
Buy
|
8,100
|
$1.80
|
Common Stock
|
||||
10/12/2017
|
Buy
|
300
|
$1.81
|
Common Stock
|
||||
10/12/2017
|
Buy
|
2,200
|
$1.82
|
Common Stock
|
||||
10/12/2017
|
Buy
|
1,700
|
$1.81
|
Common Stock
|
||||
10/12/2017
|
Buy
|
4,000
|
$1.82
|
Common Stock
|
||||
10/9/2017
|
Buy
|
9,900
|
$1.85
|
Common Stock
|
||||
10/9/2017
|
Buy
|
9,900
|
$1.86
|
Common Stock
|
Trade Date | Buy/Sell | Trade Quantity | Net Price | Security Description | ||||
10/6/2017
|
Buy
|
900
|
$1.83
|
Common Stock
|
||||
10/6/2017
|
Buy
|
1,000
|
$1.83
|
Common Stock
|
||||
10/6/2017
|
Buy
|
1,600
|
$1.86
|
Common Stock
|
||||
10/6/2017
|
Buy
|
8,300
|
$1.87
|
Common Stock
|
||||
10/6/2017
|
Buy
|
5,252
|
$1.85
|
Common Stock
|
||||
10/6/2017
|
Buy
|
5,101
|
$1.90
|
Common Stock
|
||||
10/6/2017
|
Buy
|
300
|
$1.92
|
Common Stock
|
||||
10/6/2017
|
Buy
|
900
|
$1.91
|
Common Stock
|
||||
10/6/2017
|
Buy
|
8,700
|
$1.91
|
Common Stock
|
||||
10/6/2017
|
Buy
|
3,350
|
$1.91
|
Common Stock
|
||||
10/5/2017
|
Buy
|
8,100
|
$1.89
|
Common Stock
|
||||
10/5/2017
|
Buy
|
900
|
$1.90
|
Common Stock
|
||||
10/5/2017
|
Buy
|
900
|
$1.90
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.92
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.90
|
Common Stock
|
||||
10/5/2017
|
Buy
|
100
|
$1.93
|
Common Stock
|
||||
10/5/2017
|
Buy
|
2,400
|
$1.91
|
Common Stock
|
||||
10/5/2017
|
Buy
|
2,400
|
$1.91
|
Common Stock
|
||||
10/5/2017
|
Buy
|
5,000
|
$1.91
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.91
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.91
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.88
|
Common Stock
|
||||
10/5/2017
|
Buy
|
100
|
$1.95
|
Common Stock
|
||||
10/5/2017
|
Buy
|
400
|
$1.90
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,400
|
$1.90
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.90
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.91
|
Common Stock
|
||||
10/5/2017
|
Buy
|
3,700
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
1,200
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
1,200
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
700
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
1,196
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
4,300
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
404
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
300
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
1,300
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
3,400
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
4,000
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
1,900
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
2,100
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
4,000
|
$1.94
|
Common Stock
|
||||
10/5/2017
|
Buy
|
100
|
$1.79
|
Common Stock
|
||||
10/5/2017
|
Buy
|
3,000
|
$1.75
|
Common Stock
|
||||
10/5/2017
|
Buy
|
100
|
$1.75
|
Common Stock
|
||||
10/5/2017
|
Buy
|
4,300
|
$1.75
|
Common Stock
|
||||
10/5/2017
|
Buy
|
5,000
|
$1.77
|
Common Stock
|
||||
10/5/2017
|
Buy
|
600
|
$1.78
|
Common Stock
|
||||
10/5/2017
|
Buy
|
4,300
|
$1.78
|
Common Stock
|
||||
10/5/2017
|
Buy
|
8,400
|
$1.78
|
Common Stock
|
||||
10/5/2017
|
Buy
|
1,400
|
$1.78
|
Common Stock
|
||||
10/5/2017
|
Buy
|
100
|
$1.78
|
Common Stock
|
||||
10/5/2017
|
Buy
|
9,900
|
$1.78
|
Common Stock
|
||||
10/4/2017
|
Buy
|
9,900
|
$1.84
|
Common Stock
|
||||
10/4/2017
|
Buy
|
2,500
|
$1.84
|
Common Stock
|
||||
9/26/2017
|
Buy
|
9,900
|
$1.54
|
Common Stock
|
||||
9/25/2017
|
Buy
|
3,500
|
$1.51
|
Common Stock
|
||||
9/25/2017
|
Buy
|
9,900
|
$1.51
|
Common Stock
|
Trade Date | Buy/Sell | Trade Quantity | Net Price | Security Description | ||||
9/25/2017
|
Buy
|
2,800
|
$1.51
|
Common Stock
|
||||
9/25/2017
|
Buy
|
7,100
|
$1.51
|
Common Stock
|
||||
9/25/2017
|
Buy
|
6,400
|
$1.51
|
Common Stock
|
||||
9/25/2017
|
Buy
|
2,100
|
$1.49
|
Common Stock
|
||||
9/25/2017
|
Buy
|
9,900
|
$1.51
|
Common Stock
|
||||
9/25/2017
|
Buy
|
1,100
|
$1.53
|
Common Stock
|
||||
9/25/2017
|
Buy
|
8,800
|
$1.53
|
Common Stock
|
||||
9/25/2017
|
Buy
|
1,400
|
$1.54
|
Common Stock
|
||||
9/25/2017
|
Buy
|
8,500
|
$1.54
|
Common Stock
|
||||
9/25/2017
|
Buy
|
6,800
|
$1.55
|
Common Stock
|
||||
9/25/2017
|
Buy
|
3,100
|
$1.55
|
Common Stock
|
||||
9/25/2017
|
Buy
|
726
|
$1.56
|
Common Stock
|
||||
9/22/2017
|
Buy
|
9,900
|
$1.49
|
Common Stock
|
||||
9/22/2017
|
Buy
|
7,599
|
$1.50
|
Common Stock
|
||||
9/21/2017
|
Buy
|
9,900
|
$1.52
|
Common Stock
|
||||
9/21/2017
|
Buy
|
9,900
|
$1.50
|
Common Stock
|
||||
9/14/2017
|
Buy
|
9,900
|
$1.29
|
Common Stock
|
||||
9/12/2017
|
Buy
|
9,900
|
$1.23
|
Common Stock
|
||||
9/12/2017
|
Buy
|
9,900
|
$1.23
|
Common Stock
|
||||
9/11/2017
|
Buy
|
400
|
$1.20
|
Common Stock
|
||||
9/11/2017
|
Buy
|
9,500
|
$1.20
|
Common Stock
|
||||
9/11/2017
|
Buy
|
9,900
|
$1.26
|
Common Stock
|
||||
9/11/2017
|
Buy
|
9,900
|
$1.21
|
Common Stock
|
||||
8/9/2017
|
Buy
|
57
|
$1.56
|
Common Stock
|
||||
8/9/2017
|
Buy
|
9,900
|
$1.52
|
Common Stock
|
||||
8/9/2017
|
Buy
|
9,843
|
$1.52
|
Common Stock
|
||||
8/9/2017
|
Buy
|
300
|
$1.50
|
Common Stock
|
||||
8/9/2017
|
Buy
|
300
|
$1.48
|
Common Stock
|
||||
5/11/2017
|
Buy
|
90
|
$4.27
|
Common Stock
|
||||
5/11/2017
|
Buy
|
5,000
|
$4.13
|
Common Stock
|
||||
12/12/2016
|
Buy
|
5,000
|
$6.50
|
Common Stock
|
||||
12/6/2016
|
Buy
|
9,900
|
$6.86
|
Common Stock
|
||||
12/1/2016
|
Buy
|
9,900
|
$6.92
|
Common Stock
|
||||
12/1/2016
|
Buy
|
9,900
|
$7.04
|
Common Stock
|
||||
10/6/2016
|
Buy
|
9,000
|
$7.30
|
Common Stock
|
||||
10/5/2016
|
Buy
|
1,231
|
$7.41
|
Common Stock
|
||||
10/5/2016
|
Buy
|
320
|
$7.45
|
Common Stock
|
||||
10/5/2016
|
Buy
|
2,800
|
$7.45
|
Common Stock
|
||||
10/5/2016
|
Buy
|
200
|
$7.43
|
Common Stock
|
||||
10/5/2016
|
Buy
|
260
|
$7.44
|
Common Stock
|
||||
10/5/2016
|
Buy
|
5,089
|
$7.45
|
Common Stock
|
||||
10/4/2016
|
Buy
|
200
|
$7.47
|
Common Stock
|
||||
10/4/2016
|
Buy
|
9,700
|
$7.44
|
Common Stock
|
||||
10/4/2016
|
Buy
|
6,794
|
$7.38
|
Common Stock
|
||||
10/3/2016
|
Buy
|
200
|
$7.13
|
Common Stock
|
||||
10/3/2016
|
Buy
|
200
|
$7.20
|
Common Stock
|
||||
10/3/2016
|
Buy
|
200
|
$7.26
|
Common Stock
|
||||
10/3/2016
|
Buy
|
5,000
|
$7.32
|
Common Stock
|
||||
10/3/2016
|
Buy
|
200
|
$7.34
|
Common Stock
|
||||
10/3/2016
|
Buy
|
200
|
$7.31
|
Common Stock
|
||||
10/3/2016
|
Buy
|
700
|
$7.31
|
Common Stock
|
||||
10/3/2016
|
Buy
|
400
|
$7.38
|
Common Stock
|
||||
10/3/2016
|
Buy
|
600
|
$7.36
|
Common Stock
|
||||
10/3/2016
|
Buy
|
1,100
|
$7.43
|
Common Stock
|
||||
9/30/2016
|
Buy
|
2,000
|
$6.68
|
Common Stock
|
||||
9/30/2016
|
Buy
|
100
|
$6.65
|
Common Stock
|
||||
9/30/2016
|
Buy
|
100
|
$6.67
|
Common Stock
|
Trade Date | Buy/Sell | Trade Quantity | Net Price | Security Description | ||||
9/30/2016
|
Buy
|
300
|
$6.69
|
Common Stock
|
||||
9/30/2016
|
Buy
|
1,600
|
$6.78
|
Common Stock
|
||||
9/30/2016
|
Buy
|
400
|
$6.78
|
Common Stock
|
||||
9/30/2016
|
Buy
|
1,500
|
$6.90
|
Common Stock
|
||||
9/30/2016
|
Buy
|
259
|
$6.90
|
Common Stock
|
||||
9/30/2016
|
Buy
|
8,141
|
$6.90
|
Common Stock
|
||||
9/30/2016
|
Buy
|
400
|
$6.94
|
Common Stock
|
||||
9/30/2016
|
Buy
|
6,100
|
$6.95
|
Common Stock
|
||||
9/30/2016
|
Buy
|
7,800
|
$7.05
|
Common Stock
|
||||
9/30/2016
|
Buy
|
600
|
$7.11
|
Common Stock
|
||||
9/30/2016
|
Buy
|
2,398
|
$7.10
|
Common Stock
|
||||
9/30/2016
|
Buy
|
302
|
$7.07
|
Common Stock
|
||||
9/30/2016
|
Buy
|
5,600
|
$7.09
|
Common Stock
|
||||
9/30/2016
|
Buy
|
1,000
|
$7.09
|
Common Stock
|
||||
9/30/2016
|
Buy
|
602
|
$7.11
|
Common Stock
|
||||
9/30/2016
|
Buy
|
9,298
|
$7.14
|
Common Stock
|
||||
9/29/2016
|
Buy
|
1,800
|
$6.40
|
Common Stock
|
||||
9/29/2016
|
Buy
|
1,300
|
$6.47
|
Common Stock
|
||||
9/29/2016
|
Buy
|
200
|
$6.53
|
Common Stock
|
||||
9/29/2016
|
Buy
|
100
|
$6.49
|
Common Stock
|
||||
9/29/2016
|
Buy
|
180
|
$6.54
|
Common Stock
|
||||
9/23/2016
|
Buy
|
84
|
$6.44
|
Common Stock
|
||||
9/21/2016
|
Buy
|
700
|
$5.75
|
Common Stock
|
||||
9/21/2016
|
Buy
|
9,900
|
$5.90
|
Common Stock
|
||||
9/21/2016
|
Buy
|
9,200
|
$5.88
|
Common Stock
|
||||
9/21/2016
|
Buy
|
9,900
|
$5.82
|
Common Stock
|
||||
9/21/2016
|
Buy
|
9,900
|
$5.95
|
Common Stock
|
Trade Date
|
Settlement Date
|
Buy/Sell
|
Trade Quantity
|
Net Price
|
Security Description
|
|||||
12/07/2017
|
12/11/2017
|
Buy
|
15,000
|
$2.1710
|
Common Stock
|
|||||
12/01/2017
|
12/05/2017
|
Buy
|
5,000
|
$2.4800
|
Common Stock
|
|||||
12/01/2017
|
12/05/2017
|
Buy
|
4,000
|
$2.5000
|
Common Stock
|
|||||
12/01/2017
|
12/05/2017
|
Buy
|
2,992
|
$2.5500
|
Common Stock
|
|||||
12/01/2017
|
12/05/2017
|
Buy
|
8
|
$2.5500
|
Common Stock
|
|||||
12/01/2017
|
12/05/2017
|
Buy
|
2,000
|
$2.5800
|
Common Stock
|
|||||
12/01/2017
|
12/05/2017
|
Buy
|
1,100
|
$2.6000
|
Common Stock
|
|||||
11/30/2017
|
12/04/2017
|
Buy
|
100
|
$2.5900
|
Common Stock
|
|||||
11/30/2017
|
12/04/2017
|
Buy
|
400
|
$2.6500
|
Common Stock
|
|||||
11/30/2017
|
12/04/2017
|
Buy
|
300
|
$2.6700
|
Common Stock
|
|||||
11/30/2017
|
12/04/2017
|
Buy
|
200
|
$2.6700
|
Common Stock
|
|||||
11/30/2017
|
12/04/2017
|
Buy
|
600
|
$2.6800
|
Common Stock
|
|||||
11/30/2017
|
12/04/2017
|
Buy
|
1,000
|
$2.6800
|
Common Stock
|
|||||
11/29/2017
|
12/01/2017
|
Buy
|
849
|
$2.6800
|
Common Stock
|
|||||
11/29/2017
|
12/01/2017
|
Buy
|
151
|
$2.6800
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
5,000
|
$2.6000
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
500
|
$2.6400
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
500
|
$2.6500
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
500
|
$2.6800
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
400
|
$2.6900
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
100
|
$2.6900
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
500
|
$2.7200
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
460
|
$2.7700
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
40
|
$2.7700
|
Common Stock
|
Trade Date | Settlement Date | Buy/Sell | Trade Quantity | Net Price | Security Description | |||||
11/16/2017
|
11/20/2017
|
Buy
|
4,000
|
$2.7900
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
3,000
|
$2.8000
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
400
|
$2.8100
|
Common Stock
|
|||||
11/16/2017
|
11/20/2017
|
Buy
|
100
|
$2.8100
|
Common Stock
|
|||||
11/15/2017
|
11/17/2017
|
Buy
|
1,000
|
$2.8200
|
Common Stock
|
|||||
11/15/2017
|
11/17/2017
|
Buy
|
1,000
|
$2.8300
|
Common Stock
|
|||||
11/15/2017
|
11/17/2017
|
Buy
|
8,000
|
$2.8300
|
Common Stock
|
|||||
11/15/2017
|
11/17/2017
|
Buy
|
989
|
$2.8500
|
Common Stock
|
|||||
11/15/2017
|
11/17/2017
|
Buy
|
10
|
$2.8500
|
Common Stock
|
|||||
11/15/2017
|
11/17/2017
|
Buy
|
1
|
$2.8500
|
Common Stock
|
|||||
11/14/2017
|
11/16/2017
|
Buy
|
4,000
|
$2.8500
|
Common Stock
|
|||||
11/14/2017
|
11/16/2017
|
Buy
|
500
|
$2.8500
|
Common Stock
|
|||||
11/14/2017
|
11/16/2017
|
Buy
|
5,000
|
$2.8500
|
Common Stock
|
|||||
11/14/2017
|
11/16/2017
|
Buy
|
8,000
|
$2.8500
|
Common Stock
|
|||||
11/03/2017
|
11/07/2017
|
Buy
|
1,000
|
$2.3000
|
Common Stock
|
|||||
11/02/2017
|
11/06/2017
|
Buy
|
5,000
|
$2.4500
|
Common Stock
|
|||||
10/16/2017
|
10/18/2017
|
Buy
|
1,000
|
$1.6000
|
Common Stock
|
|||||
10/13/2017
|
10/17/2017
|
Buy
|
13,515
|
$1.7928
|
Common Stock
|
|||||
10/11/2017
|
10/13/2017
|
Buy
|
13,300
|
$1.8765
|
Common Stock
|
|||||
10/06/2017
|
10/11/2017
|
Buy
|
13,666
|
$1.8802
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
8,200
|
$1.5100
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
3,114
|
$1.5097
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
100
|
$1.5100
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
175
|
$1.5100
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
25
|
$1.5100
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
200
|
$1.5100
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
400
|
$1.5100
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
1,100
|
$1.5100
|
Common Stock
|
|||||
09/22/2017
|
09/26/2017
|
Buy
|
200
|
$1.5100
|
Common Stock
|
|||||
01/18/2017
|
N/A
|
Journaled Shares
|
4,411
|
$5.3099
|
Common Stock
|
|||||
12/05/2016
|
12/08/2016
|
Buy
|
611
|
$6.8000
|
Common Stock
|
|||||
12/05/2016
|
12/08/2016
|
Buy
|
3,800
|
$6.8000
|
Common Stock
|
|
||||||||
|
|
Common Stock
|
|
|||||
Name and Address of Beneficial Owner (a)
|
|
Amount and Nature of
Beneficial Ownership (#) |
|
|
Percent
of Class (%) (b) |
|
||
Ronald J. Masciantonio
|
|
|
300,687
|
(c)
|
|
|
2.0
|
%
|
David Stern
|
|
|
182,545
|
(d)
|
|
|
1.2
|
%
|
Michael J. Blitzer
|
|
|
28,522
|
(e)
|
|
|
*
|
|
Barry Erdos
|
|
|
81,147
|
(f)
|
|
|
*
|
|
Peter P. Longo
|
|
|
8,000
|
(e)
|
|
|
*
|
|
Pierre-André Mestre
|
|
|
1,927,820
|
(e)(g)
|
|
|
13.1
|
%
|
Anthony M. Romano
|
|
|
0
|
|
|
|
0
|
%
|
Melissa Payner-Gregor
|
|
|
35,376
|
|
|
|
*
|
|
B. Allen Weinstein
|
|
|
29,600
|
|
|
|
*
|
|
Yeled Invest S.A.
|
|
|
1,922,820
|
(g)
|
|
|
13.1
|
%
|
9B, Boulevard Du Prince Henri
|
|
|
|
|||||
Luxembourg N4 L-1724
|
|
|
|
|||||
Nathan G. Miller
|
|
|
1,136,727
|
(h)
|
|
|
7.7
|
%
|
347 Lukes Wood Road
|
|
|
|
|||||
New Canaan, CT 06840
|
|
|
|
|||||
Renaissance Technologies LLC
|
|
|
775,100
|
(i)
|
|
|
5.3
|
%
|
800 Third Avenue
|
|
|
|
|||||
New York, NY 10022
|
|
|
|
|||||
Royce and Associates, LP
|
|
|
769,967
|
(j)
|
|
|
5.2
|
%
|
745 Fifth Avenue
|
|
|
|
|||||
New York, NY 10151
|
|
|
|
|||||
All current directors and officers as a group (7 persons)
|
|
|
2,564,097
|
(k)
|
|
|
17.3
|
%
|
*
|
Less than 1% of the outstanding Common Stock or less than 1% of the voting power.
|
(a)
|
Except as otherwise indicated, the address of each person named in the table is: c/o Destination Maternity Corporation, 232 Strawbridge Drive, Moorestown, New Jersey 08057.
|
(b)
|
Based upon 15,004,667 shares of Common Stock issued and outstanding as of April 20, 2018.
|
(c)
|
Includes 100,000 shares of unvested restricted stock from the October 19, 2017 grant of 100,000 shares, which shares vest in four equal annual installments of 25,000 shares on each of October 19, 2018, October 19, 2019, October 19, 2020, and October 19, 2021, 2,035 shares of unvested restricted stock from the December 5, 2014 grant of 8,138 shares, which shares vest on December 5, 2018, 5,842 shares of unvested restricted stock from the March 30, 2016 grant of 11,683 shares, of which 2,921 shares vest on each of March 30, 2019, and March 30, 2020, and 35,000 shares of unvested restricted stock, the grant of which has been approved with an effective grant date of April 20, 2018, with vesting to occur in four equal installments on April 20, 2019, April 20, 2020, April 20, 2021 and April 20, 2022. Also includes 125,964 shares purchasable upon exercise of stock options owned (or which may be deemed to be owned) as of April 23, 2018 or 60 days thereafter.
|
(d)
|
Includes 100,000 shares of unvested restricted stock from the October 19, 2017 grant of 100,000 shares, which shares vest in four equal annual installments of 25,000 shares on each of October 19, 2018, October 19, 2019, October 19, 2020, and October 19, 2021, 11,677 shares of unvested restricted stock from the August 1, 2016 grant of 15,569 shares, of which 3,892 shares vested on August 1, 2017, 3,892 shares will vest on each of August 1, 2018 and August 1, 2019, and 3,983 shares vest on August 1, 2020 and 35,000 shares of unvested restricted stock, the grant of which has been approved with an effective grant date of April 20, 2018, with vesting to occur in four equal installments on April 20, 2019, April 20, 2020, April 20, 2021 and April 20, 2022. Also includes 18,313 shares purchasable upon exercise of stock options owned (or which may be deemed to be owned) as of April 23, 2018 or 60 days thereafter.
|
(e)
|
Includes 4,000 shares of unvested restricted stock that would be granted upon completion of the Annual Meeting under the Company’s Non-Employee Director Compensation Policy, if such director is re-elected at the Annual Meeting.
|
(f)
|
Includes 6,000 shares of unvested restricted stock that would be granted upon completion of the Annual Meeting under the Company’s Non-Employee Director Compensation Policy, if Mr. Erdos is re-elected at the Annual Meeting and is appointed as Non-Executive
|
Chairman of the Board of Directors. | |
(g)
|
Information is based on the Schedule 13D/A filed with the SEC on April 4, 2018. According to that filing, Yeled is the beneficial owner of and has sole power to vote, dispose or direct the disposition of is the beneficial owner of and has sole power to vote, dispose or direct the disposition of 1,921,820 of the shares specified in on the above table. In addition, as a result of its ownership of a controlling interest in Orchestra, Yeled is deemed to beneficially own and have shared power to vote, dispose or direct the disposition of 1,000 of the shares specified on the above table. Mr. Mestre, a director of the Company, (i) is the Chairman of Orchestra, which is a majority owned subsidiary of Yeled, and (ii) indirectly owns a majority equity interest in Yeled.
|
(h)
|
Information is based on the Schedule 13D/A filed with the SEC on April 20, 2018. According to that filing, Mr. Miller beneficially owns all of the shares specified on the above table.
|
(i)
|
Information is based on the Schedule 13G/A filed with the SEC on February 14, 2018. According to that filing, Renaissance Technologies LLC (“RTC”), and Renaissance Technologies Holdings Corporation (“RTHC”), because of RTHC’s majority ownership of RTC, beneficially own all of the shares specified on the above table. Also according to that filing, certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the shares.
|
(j)
|
Information is based on the Schedule 13G/A filed with the SEC on January 22, 2018. According to that filing, Royce & Associates, LLC beneficially owns all of the shares specified on the above table.
|
(k)
|
Includes the following number of shares purchasable upon exercise of stock options owned (or which may be deemed to be owned) by the following persons as of April 23, 2018 or 60 days thereafter: Ronald J. Masciantonio—125,964 and David Stern—18,313. Also includes the following number of shares of unvested restricted stock owned (or which may be deemed to be owned) by the following persons: Ronald J. Masciantonio—142,877, David Stern—146,677, Barry Erdos—6,000, Peter P. Longo—4,000, Pierre-André Mestre—4,000.
|
|
|
VOTE BY INTERNET
|
www.proxyvoting.com/NGM
|
|
|
Use the Internet to transmit your voting instructions until 11:59 p.m., Eastern Time, on May 22, 2018. Have your proxy card in hand when you access the web site www.proxyvoting.com/NGM and follow the instructions to obtain your records and to create an electronic voting instruction form.
|
|
|
|
OR
|
|
|
|
VOTE BY TELEPHONE
|
877-550-3742
|
|
|
Use any touch-tone telephone to transmit your voting instructions until 11:59 p.m., Eastern Time, on May 22, 2018. Have your proxy card in hand when you call 877-550-3742 and then follow the instructions.
|
|
|
|
OR
|
|
|
|
VOTE BY MAIL
|
|
|
|
Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided to:
Proxy Services Corporation 2180 Fifth Avenue Ronkonkoma, NY 11779 |
|
|
|
Even if you vote your proxy by Internet or by telephone, please mail back your proxy card. Your Internet or telephone vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card.
|
|
|
|||
|
|
CONTROL NUMBER
|
|
Destination Maternity Corporation
|
GOLD PROXY CARD
|
Proposal 1:
|
Mr. Miller’s Proposal to Elect Directors.
|
|
|
|
|
Nominees:
|
(1) Holly N. Alden
|
(3) Marla A. Ryan
|
|
||
|
(2) Christopher B. Morgan
|
(4) Anne-Charlotte Windal
|
|
FOR ALL ❑
|
WITHHOLD ALL ❑
|
FOR ALL EXCEPT THE NOMINEE(S) WRITTEN BELOW ❑
|
THE PARTICIPANTS RECOMMEND THAT YOU VOTE “FOR” PROPOSAL 2:
|
|
FOR
|
AGAINST
|
ABSTAIN
|
|
Proposal 2. To approve Mr. Miller’s proposal to repeal each provision of, or amendment to, the Bylaws of the Company, effective December 22, 2016 (the “Bylaws”) adopted by the Board without the approval of the stockholders of the Company subsequent to December 22, 2016 and up to and including the conclusion of the 2018 Annual Meeting.
|
|
☐
|
☐
|
☐
|
|
THE PARTICIPANTS RECOMMEND THAT YOU VOTE “FOR” PROPOSAL 3:
|
|
FOR
|
AGAINST
|
ABSTAIN
|
|
Proposal 3. To approve the ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for fiscal year ending February 2, 2019.
|
|
☐
|
☐
|
☐
|
|
THE PARTICIPANTS RECOMMEND THAT YOU VOTE “AGAINST” PROPOSAL 4:
|
|
FOR
|
AGAINST
|
ABSTAIN
|
|
Proposal 4. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the 2018 Annual Meeting.
|
|
☐
|
☐
|
☐
|
|
|
|
Date
|
|
|
|
|
Signature (Capacity)
|
|
|
|
|
Signature (If jointly held)
|
|
|
|
|
Please sign exactly as your name(s) is (are) shown on the share certificate to which the proxy applies. When shares are held by joint tenants, both should sign. When signing as an attorney, executor, administrator, trustee or guardian, please give full title as such. If a corporation, please sign in full corporate name by President or other authorized officer. If a partnership, please sign in partnership name by authorized person.
|
|
PLEASE SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.
|
|
|
DESTINATION MATERNITY CORPORATION
|
GOLD PROXY CARD
|